Profile data is unavailable for this security.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi XDC Cayman Inc | 2.28bn | 304.59m | 19.10bn | 1.18k | 57.26 | 3.26 | 51.88 | 8.37 | 0.2784 | 0.2784 | 2.12 | 4.89 | -- | -- | -- | 1,936,789.00 | -- | -- | -- | -- | 26.35 | -- | 13.35 | -- | 4.03 | -- | 0.0005 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
HUTCHMED (China) Ltd | 6.54bn | 787.06m | 23.74bn | 1.99k | 30.37 | 4.16 | 27.82 | 3.63 | 0.8973 | 0.8973 | 7.61 | 6.55 | 0.7258 | 7.19 | 7.69 | 3,292,013.00 | 8.76 | -14.35 | 13.36 | -20.43 | 54.12 | 36.57 | 12.06 | -31.44 | 2.60 | -- | 0.1038 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
China Resources Pharmaceutical Group Ltd | 262.87bn | 4.14bn | 35.87bn | 72.99k | 8.66 | 0.7266 | 3.05 | 0.1365 | 0.659 | 0.659 | 41.84 | 7.86 | 1.06 | 7.06 | 3.84 | 3,601,697.00 | 3.36 | 3.02 | 12.72 | 11.35 | 15.67 | 15.72 | 3.18 | 2.87 | 1.09 | 8.70 | 0.412 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
Sino Biopharmaceutical Ltd | 28.14bn | 1.98bn | 51.30bn | 25.81k | 25.51 | 1.53 | 8.49 | 1.82 | 0.107 | 0.1352 | 1.52 | 1.78 | 0.4104 | 2.31 | 5.73 | 1,090,628.00 | 7.23 | 13.11 | 13.37 | 21.74 | 80.95 | 80.37 | 17.61 | 27.47 | 0.9649 | 11.83 | 0.2479 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
Innovent Biologics Inc | 6.67bn | -1.10bn | 60.24bn | 4.87k | -- | 4.46 | -- | 9.04 | -0.7001 | -0.7001 | 4.27 | 8.30 | 0.3248 | 0.9481 | 7.85 | 1,368,407.00 | -5.38 | -13.06 | -6.80 | -15.85 | 81.69 | 84.51 | -16.56 | -43.44 | 2.78 | -162.51 | 0.2242 | -- | 36.21 | 265.79 | 52.83 | -- | 34.60 | -- |
CSPC Pharmaceutical Group Ltd | 34.78bn | 6.51bn | 73.16bn | 23.50k | 11.21 | -- | 12.47 | 2.10 | 0.5488 | 0.5488 | 2.93 | -- | -- | -- | -- | 1,480,162.00 | -- | 16.08 | -- | 21.57 | 71.51 | 72.95 | 19.25 | 19.63 | -- | -- | -- | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
Hansoh Pharmaceutical Group Company Ltd | 10.85bn | 3.52bn | 94.85bn | 9.12k | 27.39 | 3.42 | 24.23 | 8.74 | 0.5834 | 0.5834 | 1.80 | 4.68 | 0.3206 | 2.02 | 3.00 | 1,189,743.00 | 10.40 | 11.58 | 12.24 | 13.98 | 89.78 | 90.78 | 32.44 | 29.28 | 4.12 | -- | 0.143 | 12.75 | 7.69 | 5.52 | 26.85 | 11.49 | -10.45 | -- |
Data as of Jul 05 2024. Currency figures normalised to Hansoh Pharmaceutical Group Company Ltd's reporting currency: Hong Kong Dollar HKD
5.31%Per cent of shares held by top holders
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 30 Apr 2024 | 81.57m | 1.37% |
The Vanguard Group, Inc.as of 06 Jun 2024 | 38.11m | 0.64% |
FIL Investment Management (Hong Kong) Ltd.as of 30 Apr 2024 | 32.86m | 0.55% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 31.49m | 0.53% |
UBS Asset Management (Hong Kong) Ltd.as of 30 Apr 2024 | 27.29m | 0.46% |
Fidelity Management & Research (Hong Kong) Ltd.as of 31 Mar 2024 | 26.67m | 0.45% |
BlackRock Fund Advisorsas of 06 Jun 2024 | 22.70m | 0.38% |
Strategic Advisers LLCas of 30 Apr 2024 | 22.67m | 0.38% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 17.24m | 0.29% |
BlackRock Advisors (UK) Ltd.as of 06 Jun 2024 | 14.80m | 0.25% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.